BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
137.06
-2.33 (-1.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close139.39
Open141.00
Bid137.07 x 800
Ask140.00 x 800
Day's Range133.13 - 142.34
52 Week Range87.49 - 199.70
Volume811,867
Avg. Volume507,811
Market Cap7.532B
Beta (3Y Monthly)3.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Top Gene-Sequencing Stocks for 2019
    Motley Fool12 hours ago

    Top Gene-Sequencing Stocks for 2019

    These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

  • Cambridge's bluebird bio expanding Kendall Square HQ
    American City Business Journalsyesterday

    Cambridge's bluebird bio expanding Kendall Square HQ

    The gene therapy company plans to expand into office and lab space directly adjacent to its current headquarters.

  • Here's Why Shares of bluebird bio Slumped Today
    Motley Fool2 days ago

    Here's Why Shares of bluebird bio Slumped Today

    No-news anxiety-selling seems to be to blame for the biotech's woes.

  • ETF Trends5 days ago

    Four Companies Could Power The New Genomics ETF

    Earlier this week, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted, giving investors a new avenue for tapping the fast-growing genomics market. GNOM tracks the Solactive Genomics Index ...

  • Motley Fool11 days ago

    Why bluebird bio Could Deliver Miracles to Genetic Disease Patients

    CAR-T therapies have the potential to work wonders in hospitals and in your portfolio.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about bluebird bio Inc.

    bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is extremely high for BLUE with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding BLUE is favorable, with net inflows of $114.61 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Motley Fool11 days ago

    5 Stocks in the Age of Miracles

    Motley Fool co-founder David Gardner shares five picks that are changing the world and bringing tomorrow closer to today.

  • Celgene & Acceleron Submit BLA for Luspatercept to the FDA
    Zacks11 days ago

    Celgene & Acceleron Submit BLA for Luspatercept to the FDA

    Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.

  • 3 High-Growth Genomics Stocks You Can Buy
    Motley Fool13 days ago

    3 High-Growth Genomics Stocks You Can Buy

    These fast-growing companies are leveraging advances in genetic insight in ways that could pay off big for investors.

  • 2 Blockbuster Gene Therapy Programs to Watch in 2019
    Motley Fool20 days ago

    2 Blockbuster Gene Therapy Programs to Watch in 2019

    A thousand gene therapies in development could get a lot more attention if these two live up to expectations this year.

  • Most Analysts Have Given bluebird bio Positive Ratings in March
    Market Realist22 days ago

    Most Analysts Have Given bluebird bio Positive Ratings in March

    Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing

  • Reuters22 days ago

    EMA panel recommends approval of Bluebird Bio's first gene therapy

    A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod. Final approval depends on the European Commission, which generally follows recommendations from the Committee on Human Medicinal Products (CHMP). Zynteglo is intended for patients 12 years and older who need regular blood transfusions to manage their disease and have no matching donor for a stem cell transplant, CHMP said https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019.

  • Celgene (CELG) Submits NDA for MS Drug to FDA for Review
    Zacks24 days ago

    Celgene (CELG) Submits NDA for MS Drug to FDA for Review

    Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

  • Massachusetts concern details plan to hire new workers in Durham
    American City Business Journals26 days ago

    Massachusetts concern details plan to hire new workers in Durham

    With the cut the cut of a ribbon this morning, Massachusetts-based Bluebird Bio's newest manufacturing family in RTP is operational – but its CEO says says more growth is already expected.

  • Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?
    Zacks28 days ago

    Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?

    Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Celgene (CELG) Submits Application for MS Drug in Europe
    Zackslast month

    Celgene (CELG) Submits Application for MS Drug in Europe

    Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.

  • Here's Why bluebird bio Gained 16.3% in February
    Motley Foollast month

    Here's Why bluebird bio Gained 16.3% in February

    The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.

  • What Are Analysts Saying About bluebird bio, Inc.’s (NASDAQ:BLUE) Earnings Outlook?
    Simply Wall St.last month

    What Are Analysts Saying About bluebird bio, Inc.’s (NASDAQ:BLUE) Earnings Outlook?

    bluebird bio, Inc.'s (NASDAQ:BLUE) most recent earnings update in December 2018 signalled that losses became smaller relative to the prior year's level - great news for investors Below is aRead More...

  • With a Stocked War Chest, bluebird bio Presses On
    Motley Fool2 months ago

    With a Stocked War Chest, bluebird bio Presses On

    The biotech is on the verge of its first approval, with three more in the works.

  • Biotech ETFs Jump on Roche-Spark Deal
    Zacks2 months ago

    Biotech ETFs Jump on Roche-Spark Deal

    The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

  • Better Buy: bluebird bio vs. Gilead Sciences
    Motley Fool2 months ago

    Better Buy: bluebird bio vs. Gilead Sciences

    Which stock wins in a battle between this up-and-coming biotech and a giant that dominates the HIV market?

  • bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks2 months ago

    bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y

    bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.